Bringing Tranexamic Acid (TXA) into practice safely, quickly and efficiently
Who is this relevant to?
Decision makers in NHS ambulance services and emergency departments in NHS Trusts
TXA is a drug that inhibits fibrinolysis (the breaking down of blood clots, which can worsen bleeding in situations such as major trauma). The National Institute for Health Research (NIHR) funded a large international study (the CRASH-2 trial) involving a total of 20,211 trauma patients from 274 hospitals in 40 countries. The result of the trial showed that, if used within three hours after trauma, TXA can reduce the risk of death from bleeding by as much as 30 per cent. Based on these findings, getting the drug to all appropriate trauma patients could save around 400 lives per year in the UK. The drug was quickly moved into routine practice by trauma teams in the military but the challenge was how best to get TXA used in the NHS ambulance service and in hospital trusts.